2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Lok ASF, McMahon BJ. AASLD practice guidline: Chronic hepatitis B: Update of recommendations. Hepatology, 2004,39:857-861. 被引量：1
7Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on management of chronic hepatitis B: an update.Hepatology, 2003, 18:239-245. 被引量：1
8Yuen MF, Wang KH,Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological,and clinical aspects. Hepatology, 2004, 39 : 1694-1701. 被引量：1
9Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatits B. Hepatology, 2003, 37:748-755. 被引量：1
10Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat, 2002, 9:208-212. 被引量：1
